Evidence map›Paper›PMID 41471310›Full record

ArticlePharmaceuticals (Basel, Switzerland)2025

A Unified Approach to Synthesizing Four Linezolid Metabolites That May Cause Thrombocytopenia.

Naoki Oikawa, Natsu Inoue, Shogo Ishii, Takumi Goto, Hiroaki Saito, Fumihiro Kurosaki, Takahiro Aoyama, Yasuhiro Tsuji, Taketo Uchiyama

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Naoki OikawaLaboratory of Medicinal Chemistry, School of Pharmacy, Nihon University, 7-7-1, Narashinodai, Funabashi 274-8555, Chiba, Japan.
Natsu InoueLaboratory of Medicinal Chemistry, School of Pharmacy, Nihon University, 7-7-1, Narashinodai, Funabashi 274-8555, Chiba, Japan.
Shogo IshiiLaboratory of Medicinal Chemistry, School of Pharmacy, Nihon University, 7-7-1, Narashinodai, Funabashi 274-8555, Chiba, Japan.
Takumi GotoLaboratory of Medicinal Chemistry, School of Pharmacy, Nihon University, 7-7-1, Narashinodai, Funabashi 274-8555, Chiba, Japan.
Hiroaki SaitoLaboratory of Medicinal Chemistry, School of Pharmacy, Nihon University, 7-7-1, Narashinodai, Funabashi 274-8555, Chiba, Japan.
Fumihiro KurosakiLaboratory of Clinical Pharmacometrics, School of Pharmacy, Nihon University, 7-7-1, Narashinodai, Funabashi 274-8555, Chiba, Japan.
Takahiro AoyamaLaboratory of Clinical Pharmacometrics, School of Pharmacy, Nihon University, 7-7-1, Narashinodai, Funabashi 274-8555, Chiba, Japan.ORCID 0000-0001-6111-8537
Yasuhiro TsujiLaboratory of Clinical Pharmacometrics, School of Pharmacy, Nihon University, 7-7-1, Narashinodai, Funabashi 274-8555, Chiba, Japan.ORCID 0000-0002-7967-2947
Taketo UchiyamaLaboratory of Medicinal Chemistry, School of Pharmacy, Nihon University, 7-7-1, Narashinodai, Funabashi 274-8555, Chiba, Japan.ORCID 0000-0001-5288-9807

Funding

Nihon University
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

linezolidmetabolitesNs strategyPNU-142300PNU-142586PNU-142618PNU-173558synthesis

Identifiers

PMID41471310
PMCPMC12735765

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.